Dorzolamide Brand Name– Trusopt
What is Dorzolamide
Dorzolamide is a carbonic anhydrase inhibitor for the treatment of glaucoma and ocular hypertension.
A related carbonic anhydrase inhibitor, acetazolamide, has poor penetration when applied to the cornea, and thus is only administered systemically.
Dorzolamide represents the culmination of a decade of research for an effective topical carbonic anhydrase inhibitor.
Dorzolamide proved to be the most potent inhibitor in the group studied, showing good tolerability and effective lowering of IOP.
Since dorzolamide is not a beta-blocker, bradycardia and/or hypotension are less likely. Dorzolamide is a sulfonamide derivative and should not be administered to patients with sulfonamide hypersensitivity.
Dorzolamide 2% ophthalmic solution (Trusopt®) was approved by the FDA December 9, 1994; marketing began June 1995.
Indications
- glaucoma
- ocular hypertension
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Side Effects
- agranulocytosis
- anaphylactoid reactions
- angioedema
- aplastic anemia
- asthenia
- blurred vision
- bronchospasm
- conjunctivitis
- contact dermatitis
- corneal edema
- dizziness
- dysgeusia
- dyspnea
- epistaxis
- headache
- hepatic necrosis
- keratitis
- lacrimation
- myopia
- nausea
- ocular irritation
- ocular pain
- paresthesias
- photophobia
- pruritus
- rash
- Stevens-Johnson syndrome
- throat irritation
- toxic epidermal necrolysis
- urticaria
- xerophthalmia
- xerostomia
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- carbonic anhydrase inhibitor hypersensitivity
- children
- closed-angle glaucoma
- contact lenses
- corneal abrasion
- geriatric
- hepatic disease
- infants
- neonates
- ocular infection
- pregnancy
- renal impairment
- sulfonamide hypersensitivity
Interactions
There are no drug interactions associated with Dorzolamide products.